PubMed Health⌕ Search

Biomedical subjects

H Toki

Publications and source records attributed to H Toki.

At least 55 records · Page 3Linked to original sources
PubMed1987

[Combination chemotherapy with mitomycin C, adriamycin and cisplatin (MAP) in advanced adenocarcinoma of the lung: clinical effect and renal toxicity].

Fourteen patients with advanced adenocarcinoma of the lung were treated with a combination chemotherapy of mitomycin C, adriamycin and cisplatin (MAP). The overall response rate was 43% with 6 partial responses. The median duration of response was 5.5 months. The median survival for responders was 17 months, versus 9 months for non-responders. Toxicity included nausea and/or vomiting, alopecia, myelosuppression and renal toxicity. The serial measurement of renal tubular function was found to be useful in detecting renal damage caused by cisplatin containing chemotherapy.

Adenocarcinoma↗
PubMed1987

[Antiemetic effects of combinations of metoclopramide, droperidol and dexamethasone for the prevention of cisplatin-induced gastro-intestinal toxicity: a randomized crossover trial].

Thirty-two patients with primary lung cancer receiving combination chemotherapy including cisplatin at a dosage of 80-120 mg/m2 were entered into an antiemetic randomized crossover trial. Patients received metoclopramide (2 mg/kg i.v. every 2 h X 5), droperidol (0.5 mg/kg i.v.) and dexamethasone (30 mg i.v.) on day 1, and metoclopramide (1mg/kg i.v. every 8 h X 3) (Regimen A) or metoclopramide and droperidol (2.5 mg i.v. every 8 h X 3) (Regimen B) on days 2 to 5. No vomiting occurred within the first 24 hours after cisplatin administration in 75% of patients. Regimen B was found to be more effective than regimen A with respect to the mean duration of vomiting (p less than 0.1), the mean duration of nausea (p less than 0.05), the mean duration of anorexia (p less than 0.05), and the mean score of the patients' opinions (p less than 0.1). When the patients were asked for their opinion of the two regimens, 39% preferred regimen B (p less than 0.05). There were no major side effects with either regimen.

Adult↗
PubMed1987

Granulocytic sarcoma of the intestine as a primary manifestation nine months prior to overt acute myelogenous leukemia.

A case of granulocytic sarcoma is reported. A 51-year-old male was found, upon laparotomy, to have a tumor mass in the terminal ileum. Nine months later, acute myelogenous leukemia (AML) was diagnosed upon a peripheral blood and bone marrow examination showing an increased number of abnormal myeloblasts. Scattered lesions of granulocytic sarcoma were found in the intestine, colon, testis, skin, gingiva and bone marrow. Chemotherapy, with multiple regimens for leukemia in combination, did not affect the tumor and the patient died 10 months following his development of overt leukemia. Detailed pathological findings are presented because of the difficulty in differentiating granulocytic sarcoma from non-Hodgkin's lymphoma.

Humans↗
PubMed1987

[A case of non-Hodgkin's lymphoma manifesting an eyelid tumor as a major symptom].

It is well known that a majority of non-Hodgkin's lymphoma (NHL) in the head and neck region arises from the Waldeyer's ring and neck lymph nodes. This report covers a rare case of a 69 year-old male with a symptom like the Mikulicz syndrome, who was diagnosed as having the NHL of B-cell type. This patient has been in complete remission following local radiotherapy for the tumor of the eyelid.

Aged↗
PubMed1986

[Serological study of the antibody to the adult T-cell leukemia-virus-associated antigen in various hematological diseases].

A serological study of antibody to adult T-cell leukemia-virus-associated antigen (anti-HTLV-I antibody) was made in 170 cases of various hematological diseases at Shikoku Cancer Center Hospital. The titer of anti-HTLV-I antibody was determined by indirect immunofluorescence using the MT-2 cell line. Two of two patients with ATL were positive for antibody. In non-Hodgkin's lymphoma, six of 18 cases of T-cell phenotype were positive (33%), while two of 29 cases of B-cell phenotype were antibody-positive (7%). Some cases of leukemia and aplastic anemia, who had received multiple blood transfusions, were found to be seropositive. Our results suggest that anti-HTLV-I antibody may be related to non-Hodgkin's lymphoma with T-cell phenotype as well as ATL.

Adult↗
PubMed1986

[A phase II study of epirubicin in malignant lymphoma].

A new anthracycline analog, epirubicin (4'-epi-Adriamycin) was evaluated at eleven institutes in a phase II clinical study in patients with malignant lymphoma. Epirubicin was administered intravenously mainly with using the following two regimens; 50 to 60 mg/m2 every three weeks and 40 mg/m2 weekly. A total of 46 cases were entered into the study and 41 cases were evaluable. Clinical responses, complete plus partial remissions, were observed in 27 cases (65.9%) with 8 of these showing complete remission. There was no significant difference of response between the two regimens. Response rates taking into account previous chemotherapy were 90.9% (10/11) in previously nontreated cases, 61.9% (8/13) in cases previously treated with non-anthracyclines and 52.9% (9/17) in cases treated with anthracyclines. The major adverse effect was bone marrow suppression; leukopenia was observed in 83.8%, anemia in 60.5% and thrombocytopenia in 15.4%. Other adverse effects frequently observed were anorexia (59.0%), nausea-vomiting (48.8%) and alopecia (55.6%). These adverse effects seemed milder than those produced by doxorubicin. The results indicated that epirubicin seemed to be a markedly useful drug against malignant lymphoma.

Adult↗
PubMed1986

Difference in prognosis between T- and B-cell lymphomas: clinical study at Shikoku Cancer Center Hospital.

In order to determine whether the surface marker phenotypes of non-Hodgkin's lymphomas affect the prognosis, we have studied the differences in response rate and duration of survival between T- and B-cell lymphomas. Sixty-four patients who underwent first-line therapy, including combination chemotherapy and/or radiotherapy, from February 1979 to August 1985 were evaluated. With the aid of standard immunological methods and monoclonal antibodies related to T-cells and B-cells, 21 T-cell lymphomas and 21 B-cell lymphomas were identified. In the other 22 cases phenotypes were not determined mainly because of the inability to obtain fresh samples. The complete remission rate was 100% for B-cell lymphomas and 52.3% for T-cell lymphomas. The median survival time for patients with lymphomas of Stage III and IV, excluding those with low-grade histology, was nine months for T-cell lymphomas and 17 months for B-cell lymphomas. T-cell lymphomas were found to have significantly poorer prognosis than B-cell lymphomas. One patient with B-cell lymphoma and six patients in an undetermined phenotype group, who were treated with combination chemotherapy, have been alive more than three years without relapse and these patients are considered potentially cured. Our results suggest that the surface marker phenotype study of lymphoma cells as well as histological subtyping is important in prognosis and that more effective therapy is needed to improve the prognosis of T-cell lymphomas.

Antibodies, Monoclonal↗
PubMed1986

[Non-Hodgkin's lymphoma: correlation of cell surface marker phenotype with clinical features and prognosis].

The correlation of surface marker phenotype with prognosis was analysed in 64 patients with non-Hodgkin's lymphoma who had been treated in Shikoku Cancer Center Hospital. B-cell lymphomas (21 cases) had significantly better prognosis than T-cell lymphomas (21 cases). The complete remission (CR) rate was 52%, and the 50% survival time was 13 months for T-cell lymphomas. All T-cell lymphoma patients died within 31 months. In B-cell lymphomas, on the other hand, the CR rate was 100%, 50% survival time was 30 months, and there were no cases of relapse in patients who had been in continuous CR for more than 2 years. About 40% of B-cell lymphomas appeared to have the potential for cure.

Adolescent↗
PubMed1986

[Randomized crossover trial of the antiemetic effects obtained with metoclopramide and droperidol versus those obtained with metoclopramide, droperidol and methylprednisolone in patients receiving cis-platinum chemotherapy].

Twenty-four patients with lung cancer receiving cis-platinum chemotherapy were entered in an antiemetic randomized crossover trial. The effects of high-dose metoclopramide and droperidol (regimen I) were compared with those obtained with a combination of high-dose metoclopramide, droperidol and methylprednisolone (regimen II). Three patients (12.5%) treated with regimen I and 10 (43.5%) treated with regimen II had no vomiting at all (p less than 0.05). Patient preference was significantly in favor of regimen II (p less than 0.05). No Severe side effects were observed. A further trial is necessary to determine the optimal dosage and scheduling of the available agents.

Aged↗
PubMed1986

[Intrapleural chemotherapy with cisplatin and adriamycin in lung cancer with carcinomatous pleuritis].

Seventeen patients with lung cancer who had malignant pleural effusion were intrapleurally treated with cisplatin and adriamycin. According to Koyama and Saito's criteria, ten patients showed complete response, four partial response and three no change. The overall survival from the beginning of treatment was 6.0 months (2.6+ -21.4 months). The survival in patients with complete response and performance status 2 + 3 was better than that in patients with partial response and performance status 4, respectively. Toxicities were minimal. The pharmacokinetics of intrapleural non-protein-bound platinum showed a mean half-life of 20.45 hours. Intrapleural chemotherapy with cisplatin and adriamycin thus seems to be an effective modality for lung cancer with carcinomatous pleuritis.

Aged↗